Biosante Pharmaceuticals, Inc.

Pfizer Corporation

Cell Genesys, Inc.

Aduro Gvax Inc.

Medarex Inc.

Rinat Neuroscience Corporation

University of California

Immutep S.a.

Karin Ute Jooss

Helen Kim Cho

Jianmin Fang

Joseph John Binder

Thomas Harding

Andrew Simmons

Jing-Jing Qian

Minh Nguyen

Brian Gregory Pierce

Van To Tsai

Michael Robert Dermyer

Kathryn E Koprivnikar

Joyce Tsi Tan

Betty Li

Alan J Korman

Arvind Rajpal

Yasmina Noubia Abdiche

Sawsan Youssef

Jing Jing Qian

Siradanahalli Guru

Kenneth Nelson Wills

Derek John Falconer

Marianne Marcela Andrea Martinic

Paul Jason Cockle

Wei-Hsien Ho

Frederic Triebel

James Patrick Allison

Weihsien Ho

James Richard Merson

James P Allison

Brian Donahue

Jooeun Bae

Debbie Farson

Alshad Lalani

The present invention provides antagonizing antibodies that bind to programmed cell death protein 1 (PD-1) and methods of using same. The anti-PD-1 antibodies can be used therapeutically alone or in combination with other therapeutics to treat cancer and other diseases.

Anti-PD-1 antibodies and methods of use thereof

The present disclosure provides (a) isolated immunogenic PAA polypeptides; (b) isolated nucleic acid molecules encoding immunogenic PAA polypeptides; (c) vaccine compositions comprising an immunogenic PAA polypeptide or an isolated nucleic acid molecule encoding an immunogenic PAA polypeptide; (d) methods relating to uses of the polypeptides, nucleic acid molecules, and compositions; and (e) vaccine-based immunotherapy regimens which involve co-administration of a vaccine in combination with an immune-suppressive-cell inhibitor and an immune-effector-cell enhancer.

Prostate-associated antigens and vaccine-based immunotherapy regimens

The present disclosure provides (i) isolated immunogenic TAA polypeptides (i.e., an immunogenic MUC1 polypeptides, an immunogenic MSLN polypeptides, and an immunogenic TERT polypeptides), (ii) isolated nucleic acid molecules encoding one or more immunogenic TAA polypeptides, (iii) compositions comprising an immunogenic TAA polypeptide or an isolated nucleic acid molecule encoding an immunogenic TAA polypeptide, and (iv) methods relating to uses of the polypeptides, nucleic acid molecules, and compositions.

Cancer vaccines

The present invention relates to prostate cancer markers, compositions comprising such markers, and methods of using such markers to induce or increase an immune response against prostate cancer. An immune response against the markers correlates with an immune response, in particular a humoral immune response, against prostate cancer cells which immune response is preferably associated with prophylaxis of prostate cancer, treatment of prostate cancer, and/or amelioration of at least one symptom associated with prostate cancer.

Methods and compositions for treating prostate cancer or inducing a humoral immune response against prostate cancer

The present invention relates to a method of enhancing the anti-tumor response in a mammal. More particularly, the invention is concerned with combinations comprising a cytokine-secreting cell and an anti-PD-1 antibody, and methods of administering the combination for enhanced immune response to tumor cells in a patient with a cancer.

PS-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof

The present invention relates to a method of enhancing anti-tumor protection in a mammal. More particularly, the invention is concerned with combinations comprising antigen presenting cell (APC) activators and a cytokine-secreting cell and methods of administering the combination for enhanced immune response to tumor cells in a patient with a cancer.

Compositions containing LAG-3 and cells that secrete GM-CSF and methods of use

PD-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof

The present invention relates to prostate cancer markers, compositions comprising such markers, immunoglobulins specific for such markers, and methods of using such markers and/or immunoglobulins to assess an immune response against prostate cancer. An immune response against the markers correlates with an immune response, in particular a humoral immune response, against prostate cancer cells which immune response is preferably associated with prophylaxis of prostate cancer, treatment of prostate cancer, and/or amelioration of at least one symptom associated with prostate cancer.

Methods and compositions for identifying prostate cancer or a humoral immune response against prostate cancer

Cellular compositions and methods for inducing an immune response to tumor cells are described. The cellular compositions include a tumor antigen and cells that have been modified to express a cytokine and one or more of a tumor antigen, anti-CTLA4 antibody and an additional cytokine. The cellular compositions find utility in methods for treating cancer.

Cancer immunotherapy compositions and methods of use

Filamin-B peptides, compositions comprising such peptides, and methods of using such peptides to assess an immune response against such peptides are described. An immune response against the peptides correlates with an immune response, in particular a cellular immune response, against prostate cancer cells which immune response is preferably associated with prophylaxis of prostate cancer, treatment of prostate cancer, and/or amelioration of at least one symptom associated with prostate cancer.

Methods and compositions for identifying a cellular immune response against prostate cancer

Growing community of inventors

San Diego, CA, United States of America

Karin Ute Jooss